HUE065935T2 - Poliómavírust semlegesítõ antitestek - Google Patents
Poliómavírust semlegesítõ antitestekInfo
- Publication number
- HUE065935T2 HUE065935T2 HUE16766397A HUE16766397A HUE065935T2 HU E065935 T2 HUE065935 T2 HU E065935T2 HU E16766397 A HUE16766397 A HU E16766397A HU E16766397 A HUE16766397 A HU E16766397A HU E065935 T2 HUE065935 T2 HU E065935T2
- Authority
- HU
- Hungary
- Prior art keywords
- neutralizing antibodies
- polyomavirus
- polyomavirus neutralizing
- antibodies
- neutralizing
- Prior art date
Links
- 241001505332 Polyomavirus sp. Species 0.000 title 1
- 230000003472 neutralizing effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2015089764 | 2015-09-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE065935T2 true HUE065935T2 (hu) | 2024-06-28 |
Family
ID=56936456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE16766397A HUE065935T2 (hu) | 2015-09-16 | 2016-09-08 | Poliómavírust semlegesítõ antitestek |
Country Status (23)
| Country | Link |
|---|---|
| US (8) | US9862760B2 (enExample) |
| EP (2) | EP3350218B1 (enExample) |
| JP (4) | JP7053455B2 (enExample) |
| CN (2) | CN113929771B (enExample) |
| AR (1) | AR106043A1 (enExample) |
| AU (1) | AU2016322814B2 (enExample) |
| CA (1) | CA2995795A1 (enExample) |
| DK (1) | DK3350218T5 (enExample) |
| ES (1) | ES2973856T3 (enExample) |
| FI (1) | FI3350218T3 (enExample) |
| HR (1) | HRP20240413T1 (enExample) |
| HU (1) | HUE065935T2 (enExample) |
| IL (2) | IL257541B2 (enExample) |
| LT (1) | LT3350218T (enExample) |
| MX (2) | MX392098B (enExample) |
| PL (1) | PL3350218T3 (enExample) |
| PT (1) | PT3350218T (enExample) |
| RS (1) | RS65441B1 (enExample) |
| SI (1) | SI3350218T1 (enExample) |
| SM (1) | SMT202400124T1 (enExample) |
| TW (2) | TWI726911B (enExample) |
| UY (1) | UY36905A (enExample) |
| WO (1) | WO2017046676A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9862760B2 (en) | 2015-09-16 | 2018-01-09 | Novartis Ag | Polyomavirus neutralizing antibodies |
| WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| US11905331B2 (en) | 2016-11-11 | 2024-02-20 | Kumho Ht, Inc. | Antibody binding specifically to CD40 and use thereof |
| CA3083363A1 (en) * | 2017-12-01 | 2019-06-06 | Novartis Ag | Polyomavirus neutralizing antibodies |
| US10946238B1 (en) | 2018-07-23 | 2021-03-16 | Life Fitness, Llc | Exercise machines having adjustable elliptical striding motion |
| US11634485B2 (en) | 2019-02-18 | 2023-04-25 | Eli Lilly And Company | Therapeutic antibody formulation |
| US12410238B2 (en) | 2019-06-19 | 2025-09-09 | Icahn School Of Medicine At Mount Sinai | Monoclonal antibodies against JC virus |
| US20230212300A1 (en) * | 2020-05-20 | 2023-07-06 | Remd Biotherapeutics, Inc. | Human endothelin receptor a (etar) antagonist antibodies |
| RS65172B1 (sr) * | 2020-06-09 | 2024-03-29 | Memo Therapeutics Ag | Molekuli antitela protiv bk virusa |
| AU2021288699A1 (en) * | 2020-06-12 | 2023-02-09 | Novartis Ag | Dosing of polyomavirus neutralizing antibodies |
| JP2023548838A (ja) * | 2020-10-29 | 2023-11-21 | フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド | ニワトリ貧血ウイルス（ｃａｖ）に基づくベクター |
| EP4304650A4 (en) * | 2021-03-12 | 2025-05-28 | Icahn School of Medicine at Mount Sinai | NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST BK VIRUS |
| WO2023175171A1 (en) | 2022-03-18 | 2023-09-21 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Bk polyomavirus antibodies and uses thereof |
| CA3254085A1 (en) * | 2022-05-18 | 2023-11-23 | The Brigham And Women's Hospital, Inc. | KLRB1 LIAISON AGENTS AND THEIR METHODS OF USE |
| CN118725124B (zh) * | 2023-03-29 | 2025-09-16 | 东莞市朋志生物科技有限公司 | 抗胃蛋白酶原ⅱ抗体、检测胃蛋白酶原ⅱ的试剂和试剂盒 |
| WO2025111317A1 (en) * | 2023-11-21 | 2025-05-30 | The Brigham And Women's Hospital, Inc. | Klrb1 binding agents and methods of use thereof |
| WO2025252935A1 (en) | 2024-06-07 | 2025-12-11 | Universite De Strasbourg | Bkv neutralizing antibodies |
| EP4659810A1 (en) | 2024-06-07 | 2025-12-10 | Université de Strasbourg | Bkv neutralizing antibodies |
| EP4659811A1 (en) * | 2024-06-07 | 2025-12-10 | Université de Strasbourg | Bk virus neutralizing antibodies |
| WO2025252939A1 (en) * | 2024-06-07 | 2025-12-11 | Universite De Strasbourg | Bk virus neutralizing antibodies |
| CN120623324B (zh) * | 2025-08-13 | 2025-10-31 | 北京溯本源和生物科技有限公司 | 一种用于bk病毒vp1蛋白检测的单克隆抗体3c7及应用 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3720760A (en) | 1968-09-06 | 1973-03-13 | Pharmacia Ab | Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| ATE37983T1 (de) | 1982-04-22 | 1988-11-15 | Ici Plc | Mittel mit verzoegerter freigabe. |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| WO1991005548A1 (en) | 1989-10-10 | 1991-05-02 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
| JP2571874B2 (ja) | 1989-11-06 | 1997-01-16 | アルカーメス コントロールド セラピューティクス，インコーポレイテッド | タンパク質マイクロスフェア組成物 |
| DE69232706T2 (de) | 1991-05-01 | 2002-11-28 | Henry M. Jackson Foundation For The Advancement Of Military Medicine, Rockville | Verfahren zur behandlung infektiöser respiratorischer erkrankungen |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| EP0640094A1 (en) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| JPH08511420A (ja) | 1993-06-16 | 1996-12-03 | セルテック・セラピューテイクス・リミテッド | 抗 体 |
| US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
| EP0805678B1 (en) | 1995-01-05 | 2003-10-29 | THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN | Surface-modified nanoparticles and method of making and using same |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| AU710347B2 (en) | 1995-08-31 | 1999-09-16 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
| ATE508733T1 (de) | 1996-03-04 | 2011-05-15 | Penn State Res Found | Materialien und verfahren zur steigerung der zellulären internalisierung |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| DE69732306T2 (de) | 1997-01-16 | 2006-01-12 | Massachusetts Institute Of Technology, Cambridge | Zubereitung von partikelhaltigen arzneimitteln zur inhalation |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| DE69833755T2 (de) | 1997-05-21 | 2006-12-28 | Biovation Ltd. | Verfahren zur herstellung von nicht-immunogenen proteinen |
| EP2380906A2 (en) | 1997-06-12 | 2011-10-26 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| ES2198922T3 (es) | 1998-06-24 | 2004-02-01 | Advanced Inhalation Research, Inc. | Particulas porosas grandes emitadas por un inhalador. |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP2364997A3 (en) | 1999-01-15 | 2012-07-04 | Genentech, Inc. | Polypeptide variants with altered effector function |
| ES2420835T3 (es) | 1999-04-09 | 2013-08-27 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de las moléculas inmunofuncionales |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
| US7244592B2 (en) | 2002-03-07 | 2007-07-17 | Dyax Corp. | Ligand screening and discovery |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| US7462697B2 (en) | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
| CN101107268B (zh) * | 2005-01-24 | 2012-06-27 | 剑桥抗体技术有限公司 | 针对ngf的特异性结合成员 |
| AU2008333131B2 (en) * | 2007-12-07 | 2013-10-24 | Merck Serono S/A | Humanized antibody molecules specific for IL-31 |
| US8080244B2 (en) * | 2008-11-21 | 2011-12-20 | Los Alamos National Security, Llc | Anti-influenza M2e antibody |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| BR112013016495A2 (pt) | 2010-12-27 | 2018-05-22 | Japan Health Sciences Foundation | anticorpo monoclonal que reconhece a proteína l2 do papilomavírus humano (hpv) e método para medir o título de anticorpo que neutraliza o hpv usando a mesma |
| PE20141271A1 (es) | 2011-04-01 | 2014-10-08 | Sloan Kettering Inst Cancer | Anticuerpos tipo receptor de celulas t especificos para un peptido wt1 presentado por hla-a2 |
| EP2828284B1 (en) | 2012-03-20 | 2019-05-08 | Biogen MA Inc. | Jcv neutralizing antibodies |
| US9567391B2 (en) * | 2012-03-20 | 2017-02-14 | Biogen Ma Inc. | JCV neutralizing antibodies |
| ITTO20120570A1 (it) | 2012-06-27 | 2013-12-28 | Pomona Ricerca Srl | Anticorpo monoclonale diretto contro il virus jc |
| JP6407165B2 (ja) | 2012-12-31 | 2018-10-17 | ニューリミューン ホールディング エイジー | ポリオーマウイルス関連疾患の治療および防止のための組換えヒト抗体 |
| US9931393B2 (en) | 2013-12-20 | 2018-04-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Immunogenic JC polyomavirus compositions and methods of use |
| EP3099713B1 (en) * | 2014-02-02 | 2020-01-15 | MedImmune Limited | Chimeric protein composed of ngf antagonist domain and a tnfa antagonist domain |
| US20170360926A1 (en) | 2014-12-24 | 2017-12-21 | Millennium Pharmaceuticals, Inc. | PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-alpha4beta7 INTEGRIN ANTIBODY |
| US9862760B2 (en) | 2015-09-16 | 2018-01-09 | Novartis Ag | Polyomavirus neutralizing antibodies |
| CA3083363A1 (en) | 2017-12-01 | 2019-06-06 | Novartis Ag | Polyomavirus neutralizing antibodies |
| RS65172B1 (sr) | 2020-06-09 | 2024-03-29 | Memo Therapeutics Ag | Molekuli antitela protiv bk virusa |
| AU2021288699A1 (en) | 2020-06-12 | 2023-02-09 | Novartis Ag | Dosing of polyomavirus neutralizing antibodies |
-
2016
- 2016-09-07 US US15/258,925 patent/US9862760B2/en active Active
- 2016-09-08 JP JP2018513797A patent/JP7053455B2/ja active Active
- 2016-09-08 FI FIEP16766397.0T patent/FI3350218T3/fi active
- 2016-09-08 DK DK16766397.0T patent/DK3350218T5/da active
- 2016-09-08 US US15/758,491 patent/US10450366B2/en active Active
- 2016-09-08 MX MX2018003282A patent/MX392098B/es unknown
- 2016-09-08 IL IL257541A patent/IL257541B2/en unknown
- 2016-09-08 PT PT167663970T patent/PT3350218T/pt unknown
- 2016-09-08 CN CN202111169855.3A patent/CN113929771B/zh active Active
- 2016-09-08 EP EP16766397.0A patent/EP3350218B1/en active Active
- 2016-09-08 RS RS20240355A patent/RS65441B1/sr unknown
- 2016-09-08 HR HRP20240413TT patent/HRP20240413T1/hr unknown
- 2016-09-08 LT LTEPPCT/IB2016/055339T patent/LT3350218T/lt unknown
- 2016-09-08 EP EP24158407.7A patent/EP4414385A3/en active Pending
- 2016-09-08 WO PCT/IB2016/055339 patent/WO2017046676A1/en not_active Ceased
- 2016-09-08 AU AU2016322814A patent/AU2016322814B2/en active Active
- 2016-09-08 ES ES16766397T patent/ES2973856T3/es active Active
- 2016-09-08 IL IL296800A patent/IL296800A/en unknown
- 2016-09-08 CN CN201680053963.5A patent/CN108026166B/zh active Active
- 2016-09-08 SM SM20240124T patent/SMT202400124T1/it unknown
- 2016-09-08 SI SI201631811T patent/SI3350218T1/sl unknown
- 2016-09-08 HU HUE16766397A patent/HUE065935T2/hu unknown
- 2016-09-08 PL PL16766397.0T patent/PL3350218T3/pl unknown
- 2016-09-08 CA CA2995795A patent/CA2995795A1/en active Pending
- 2016-09-13 TW TW105129740A patent/TWI726911B/zh active
- 2016-09-13 TW TW110113971A patent/TWI789744B/zh active
- 2016-09-16 UY UY0001036905A patent/UY36905A/es not_active Application Discontinuation
- 2016-09-16 AR ARP160102822A patent/AR106043A1/es unknown
-
2017
- 2017-12-01 US US15/829,115 patent/US10435460B2/en active Active
-
2018
- 2018-03-15 MX MX2022005253A patent/MX2022005253A/es unknown
- 2018-11-07 US US16/183,262 patent/US10654914B2/en active Active
-
2019
- 2019-10-18 US US16/657,855 patent/US11161894B2/en active Active
-
2021
- 2021-09-21 JP JP2021153503A patent/JP7284790B2/ja active Active
- 2021-10-15 US US17/502,910 patent/US11639378B2/en active Active
-
2023
- 2023-03-03 JP JP2023032616A patent/JP7706489B2/ja active Active
- 2023-03-17 US US18/186,064 patent/US12077571B2/en active Active
-
2024
- 2024-07-22 US US18/780,282 patent/US20250051423A1/en active Pending
-
2025
- 2025-06-30 JP JP2025110154A patent/JP2025143348A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL257541A (en) | Neutralizing antibodies to the polyoma virus | |
| IL259048A (en) | Antibodies against ror-1 | |
| ZA201708128B (en) | Tau-binding antibodies | |
| SG10201913864RA (en) | Anti-LAG-3 Antibodies | |
| ZA201705663B (en) | Anti-transthyretin antibodies | |
| ZA201800027B (en) | Tau-binding antibodies | |
| AP2017009765A0 (en) | Anti-tigit antibodies | |
| GB201521393D0 (en) | Antibodies | |
| GB201521391D0 (en) | Antibodies | |
| SG11201706126WA (en) | Anti-transthyretin antibodies | |
| GB201521382D0 (en) | Antibodies | |
| IL255323A0 (en) | Anti-fcrn antibodies | |
| ZA201705662B (en) | Anti-transthyretin antibodies | |
| GB201509907D0 (en) | Antibodies | |
| GB201522394D0 (en) | Antibodies | |
| GB201503438D0 (en) | Antibodies | |
| IL284022A (en) | Anti-transthyretin antibodies | |
| GB201518728D0 (en) | Antibodies | |
| GB201515570D0 (en) | Anti-LAG-3 antibodies | |
| GB201515572D0 (en) | Anti-LAG-3 antibodies | |
| GB201514425D0 (en) | Antibodies | |
| GB201508437D0 (en) | Antibodies | |
| GB201508444D0 (en) | Antibodies | |
| GB201507541D0 (en) | Antibodies | |
| GB201504858D0 (en) | Antibodies |